Predicting efficacy assessment of combined treatment of radiotherapy and nivolumab for NSCLC patients through virtual clinical trials using QSP modeling

Non-Small Cell Lung Cancer (NSCLC) remains one of the main causes of cancer death worldwide. In the urge of finding an effective approach to treat cancer, enormous therapeutic targets and treatment combinations are explored in clinical studies, which are not only costly, suffer from a shortage of pa...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of pharmacokinetics and pharmacodynamics 2024-08, Vol.51 (4), p.319-333
Hauptverfasser:	Schirru, Miriam, Charef, Hamza, Ismaili, Khalil-Elmehdi, Fenneteau, Frédérique, Zugaj, Didier, Tremblay, Pierre-Olivier, Nekka, Fahima
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents, Immunological - administration & dosage Antineoplastic Agents, Immunological - therapeutic use Biochemistry Biomedical and Life Sciences Biomedical Engineering and Bioengineering Biomedicine Cancer Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Non-Small-Cell Lung - radiotherapy Cell death Chemoradiotherapy - methods Clinical trials Clinical Trials as Topic - methods Humans Immune checkpoint inhibitors Immune Checkpoint Inhibitors - administration & dosage Immune Checkpoint Inhibitors - therapeutic use Lung Neoplasms - drug therapy Lung Neoplasms - pathology Lung Neoplasms - radiotherapy Models, Biological Nivolumab - administration & dosage Nivolumab - therapeutic use Non-small cell lung carcinoma Original Paper Patients Pharmacology/Toxicology Pharmacy Radiation therapy Small cell lung carcinoma Therapeutic applications Therapeutic targets Treatment Outcome Veterinary Medicine/Veterinary Science
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!